Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ruxoprubart by NovelMed Therapeutics for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Ruxoprubart is under clinical development by NovelMed Therapeutics and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData,...
Data Insights
Ruxoprubart by NovelMed Therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
Ruxoprubart is under clinical development by NovelMed Therapeutics and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)....